Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA

NCT04638153 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04638153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04638153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
December 2, 2020
Completion date
March 27, 2023
Enrollment
60 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

achondroplasia